Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hyōgo
Clinical trial register · Japan

Clinical Trials in Hyōgo, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
GlaxoSmithKline18 Hoffmann-La Roche16 Janssen Research & Development, LLC7 Gilead Sciences5 Tokyo University4
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Hyōgo

86 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Chiba-shi, Chiba, Fuchu-shi,Tokyo, Fukuoka, Himeji-shi, Hyogo, Hyōgo, Kanagawa, Kumamoto-shi, Kumamoto, Kyoto-shi, Kyoto
2026-10-26
Recruiting
Hoffmann-La Roche
Phase 3
400
Gifu, Hyōgo
2026-10-06
Recruiting
GlaxoSmithKline
Phase 3
690
Hokkaido, Hyōgo, Ibaraki
2026-09-08
Recruiting
Hoffmann-La Roche
Phase 3
380
Toyohashi, Aichi, Ehime, Gunma, Hyōgo, Kyoto, Numakunai, Okayama
2026-06-23
Recruiting
GlaxoSmithKline
Phase 3
450
Fukuoka, Hokkaido, Hyōgo, Kanagawa, Mie, Okinawa, Osaka, Saitama
2026-06-18
Recruiting
GlaxoSmithKline
Phase 3
600
Aichi, Fukuoka, Hokkaido, Hyōgo, Kanagawa, Kyoto, Mie, Numakunai
2026-06-04
Recruiting
Kyowa Kirin Co., Ltd.
Phase 2
6
Chiba, Gifu, Hyōgo, Ibaraki, Kagoshima, Kanagawa, Kyoto, Miyagi
2026-04-23
Recruiting
Takeda
Phase 2
42
Tokyo, Fukui, Hiroshima, Kanagawa, Fukuoka, Hyōgo, Yamanashi, Ehime
2026-04-22
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Hyōgo, Osaka
2025-11-18
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Hiroshima, Hyōgo, Kagawa, Kochi, Okayama, Osaka, Tokyo
2025-11-12
Recruiting
GlaxoSmithKline
Phase 2
363
Toyonaka-Shi, Aichi, Fukuoka, Hyōgo, Ibaraki, Ishikawa, Kanagawa, Mie
2025-10-30
Recruiting
Hoffmann-La Roche
Phase 3
600
Aichi, Fukuoka, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Miyagi, Niigata
2025-10-24
Active, closed
GlaxoSmithKline
Phase 2
168
Aichi, Fukuoka, Hyōgo, Kumamoto, Okayama, Tokyo
2025-08-06
Not yet open
Encapsulation-oriented vs. Timing-oriented Strategies for Necrotizing Pancreatitis
NCT07106346Walled Off Necrosis, Pancreatitis, Acute Necrotic Collection, Necrotizing Pancreatitis
Tokyo University
Not applicable
224
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kagawa, Kagoshima
2025-08-05
Recruiting
4D Molecular Therapeutics
Phase 3
480
Nagoya, Hyōgo, Fukushima, Mito, Miyazaki, Ginowan, Chiba, Fukuoka
2025-07-22
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Aichi, Hiroshima, Hyōgo, Kagawa, Kanagawa, Kochi, Kyoto, Meguro-Ku
2025-07-02
Recruiting
GlaxoSmithKline
Phase 3
981
Kitakyushu-shi, Chiba, Fukuoka, Fukushima, Gifu, Hokkaido, Hyōgo, Ibaraki
2025-06-20
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
Fukuoka, Hyōgo, Ibaraki, Kamakura, Meguro City, Mitaka, Miyagi, Toyota
2025-05-15
By invitation
Novo Nordisk A/S
Observational
30
Chiba, Fukui, Fukushima, Hyōgo, Kanagawa, Kawagoe, Miyagi, Nagano
2025-05-02
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
260
Aichi, Chiba, Fukushima, Gunma, Hiroshima, Hyōgo, Ibaraki, Kagawa
2025-04-24
Recruiting
Gilead Sciences
Phase 3
695
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kobe
2025-04-04
Active, closed
Philip Morris Products S.A.
Not applicable
290
Fukuoka, Gunma, Hyōgo, Tokyo, Yamagata, Yokohama, Yotsuya
2025-04-02
Active, closed
GlaxoSmithKline
Phase 2
307
Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima, Hokkaido, Hyōgo
2025-02-10
Recruiting
Incyte Corporation
Phase 3
240
Aichi, Aichi-ken, Fukuoka, Hiroshima, Hyōgo, Isehara Kanagawa, Kumamoto Kumamoto, Maebashi
2025-01-21
Recruiting
Janssen Research & Development, LLC
Phase 3
750
Chiba, Chūōku, Hirakata, Hyōgo, Kitakyushu-shi, Nagoya, Osaka, Ōita
2025-01-09
Recruiting
GlaxoSmithKline
Phase 3
520
Shibuya-Ku, Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hyōgo, Ibaraki
2024-12-16
Active, closed
GlaxoSmithKline
Phase 2
283
Chiba, Hokkaido, Hyōgo, Kagawa, Kumamoto, Osaka, Tokyo, Yamanashi
2024-11-11
Active, closed
Ipsen
Phase 2
670
Fukuoka, Hiroshima, Hyōgo, Kagoshima, Kyoto, Miyagi, Osaka, Shizuoka
2024-10-10
Active, closed
Hoffmann-La Roche
Phase 3
400
Chiba, Fukuoka, Gifu, Hyōgo, Kagawa, Kagoshima, Kanagawa, Nagasaki
2024-09-17
Active, closed
Software as a Medical Device for the Treatment of Patients With PTSD
NCT06589505Post-Traumatic Stress Disorder, PTSD
Otsuka Medical Devices Co., Ltd. Japan
Phase 2/3
52
Yamanashi, Akita, Fukuoka, Gunma, Hokkaido, Hyōgo, Ibaraki, Kanagawa
2024-09-01
Active, closed
Gilead Sciences
Phase 3
640
Chiba, Hyōgo, Kanagawa, Mie, Okayama, Saitama, Shizuoka, Tokyo
2024-08-28
Active, closed
Kite, A Gilead Company
Phase 3
452
Hyōgo, Nagoya, Osaka, Tochigi, Tokyo
2024-08-23
Active, closed
Incyte Biosciences Japan GK
Phase 3
21
Aichi, Fukui, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kanagawa, Kumamoto
2024-07-30
Active, closed
AstraZeneca
Observational
40
Chiba, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Mie, Okayama, Osaka
2024-07-16
Active, closed
GlaxoSmithKline
Phase 3
88
Aichi, Ehime, Fukuoka, Hokkaido, Hyōgo, Kyoto, Mie, Miyagi
2024-06-10
Active, closed
GlaxoSmithKline
Phase 2
41
Aichi, Chiba, Ehime, Fukuoka, Gunma, Hokkaido, Hyōgo, Ibaraki
2024-05-07
Active, closed
GlaxoSmithKline
Phase 4
1,358
Fukuoka, Gifu, Hiroshima, Hyōgo, Kagawa, Kagoshima, Kanagawa, Kumamoto
2024-04-16
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Funabashi Shi, Hakodate, Hyōgo, Niigata, Okayama, Sakura, Tokyo, Yokohama
2024-04-09
Recruiting
GlaxoSmithKline
Phase 3
864
Aichi, Aomori, Chiba, Ehime, Fukuoka, Gunma, Hokkaido, Hyōgo
2024-03-21
Active, closed
Gilead Sciences
Phase 2
176
Hyōgo, Jonan-ku, Minatoku, Mitaka-shi, Nagasaki, Ōita, Sagaken, Sagamihara
2023-12-05
Active, closed
GlaxoSmithKline
Phase 2
316
Aichi, Chiba, Hyōgo, Osaka, Saitama, Shizuoka, Tokyo
2023-11-14
Not yet open
WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts
NCT06133023Pancreatic Fluid Collection, Pancreatitis, Pancreatic Pseudocyst
Tokyo University
Not applicable
80
Aichi, Bunkyō-Ku, Tokyo, Chiba, Fukuoka, Gifu, Hyōgo, Kagawa, Kagoshima
2023-11
Active, closed
Stichting European Myeloma Network
Phase 3
759
Bunkyō City, Fukuoka, Hokkaido, Hyōgo, Kanazawa, Nagoya, Okayama, Osaka
2023-10-10
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kanagawa, Kyoto
2023-09-18
Recruiting
Management and Outcomes of Local Complications of Acute Pancreatitis and Postoperative Pancreatic Fistula
NCT07862088Acute Pancreatitis, Pancreatic Fluid Collection, Postoperative Pancreatic Fistula
Tokyo University
Observational
5,000
Ōtsu, Bunkyō-Ku, Tokyo, Gifu, Hyōgo, Kawagoe, Kobe, Ōsaka-sayama
2023-09-14
Active, closed
Cytokinetics
Phase 3
500
Fukuoka, Hyōgo, Ibaraki, Kanagawa, Kochi, Kyoto, Mie, Miyagi
2023-08-31
Recruiting
GlaxoSmithKline
Phase 3
892
Aichi, Chiba, Fukuoka, Hokkaido, Hyōgo, Ibaraki, Kanagawa, Kyoto
2023-08-01
Active, closed
Daiichi Sankyo
Phase 3
1,170
Ehime, Fukoka, Fukuoka, Hokkaido, Hyōgo, Ishikawa, Kanagawa, Kumamoto
2023-01-11
Recruiting
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Kyoto
2022-12-15
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
100
Ehime, Fukushima, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima, Kanagawa
2022-11-04
Active, closed
Hoffmann-La Roche
Phase 3
68
Fukuoka, Hyōgo, Kagoshima, Kumamoto, Osaka, Tokyo
2022-11-01
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Bunkyō City, Chiba, Higashiibaraki-gun, Hirakata, Hyôgo, Iruma-gun, Kanagawa, Kanazawa
2022-10-25
Active, closed
GlaxoSmithKline
Phase 2
351
Chiba, Fukuoka, Hyōgo, Kanagawa, Osaka, Saitama
2022-10-14
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Bunkyō City, Chiba, Fukuoka, Gifu, Gunma, Hirakata, Hyōgo, Kamakura-shi
2022-10-13
Active, closed
Gilead Sciences
Phase 3
1,021
Chiba, Ehime, Fukuoka, Hyōgo, Ishikawa, Kanagawa, Miyagi, Niigata
2022-10-12
Active, closed
Hoffmann-La Roche
Phase 3
122
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kanagawa, Miyagi
2022-09-27
Active, closed
Kite, A Gilead Company
Phase 3
231
Hyōgo, Kyoto, Miyagi, Okayama, Osaka
2022-09-22
Active, closed
GlaxoSmithKline
Phase 3
110
Aomori, Chiba, Gifu, Hyōgo, Miyagi, Tokyo, Wakayama, Yamanashi
2022-09-06
Active, closed
Hoffmann-La Roche
Phase 3
139
Chiba, Fukuoka, Fukushima, Hyōgo, Kanagawa, Miyagi, Osaka, Tokyo
2022-08-30
Active, closed
Genentech, Inc.
Phase 3
373
Aichi, Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kanagawa
2022-08-03
Recruiting
Immediate Necrosectomy vs. Step-up Approach for Walled-off Necrosis
NCT05451901Pancreatic Fluid Collection, Walled-off Necrosis, Pancreatitis, Acute Necrotizing, Pancreatic Pseudocyst
Tokyo University
Not applicable
70
Bunkyō-Ku, Aichi, Chiba, Gifu, Hyōgo, Kagawa, Kagoshima, Kamogawa
2022-07-29
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
15
Aichi, Fukuoka, Fukushima, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima
2022-07-12
Active, closed
Hoffmann-La Roche
Phase 2/3
97
Hyōgo, Kagoshima, Shinjuku-ku
2022-06-02
Recruiting
Innovacell GmbH
Phase 3
290
Sapporo, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kumamoto, Kyoto
2022-05-11
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Chiba, Fukuoka, Gunma, Hiroshima, Hyōgo, Ishikawa, Kanagawa, Niigata
2022-02-07
Active, closed
Gilead Sciences
Phase 3
603
Asahikawa, Chūō, Fukui, Hirakata, Hiroshima, Hyōgo, Inzai, Iwakuni
2021-11-17
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Gunma, Hyōgo, Kanagawa, Kobe, Kurume, Nagoya, Niigata, Osaka
2021-11-17
Active, closed
Janssen Pharmaceutica N.V., Belgium
Observational
1,314
Hyōgo, Meguro-ku, Osaka, Sapporo, Tokyo
2021-08-25
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Bunkyō City, Fukuoka, Hyôgo, Kanazawa, Kyoto, Nagoya, Okayama, Sapporo
2021-08-19
Active, closed
Hoffmann-La Roche
Phase 3
557
Aichi, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Osaka, Tochigi
2021-04-26
Active, closed
Incyte Biosciences Japan GK
Phase 1/2
72
Aichi, Chiba, Fukui, Fukuoka, Hyōgo, Kanagawa, Kōtoku, Kumamoto-ken
2020-12-15
Active, closed
Amgen
Phase 3
135
Fukuoka, Hokkaido, Hyōgo, Ishikawa, Kyoto, Niigata, Osaka, Tokyo
2020-12-04
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Chiba, Fukuoka, Hokkaido, Hyōgo, Miyagi, Moriguchi, Morioka, Saitama
2020-10-15
Active, closed
Hoffmann-La Roche
Phase 3
992
Aichi, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima
2020-10-09
Active, closed
Hoffmann-La Roche
Phase 3
190
Aichi, Hyōgo, Ishikawa, Kanagawa, Mie, Nagano, Nagasaki, Okayama
2020-09-30
Active, closed
Daiichi Sankyo Co., Ltd.
Phase 2
8
Tokyo, Hyōgo
2020-06-30
Active, closed
GlaxoSmithKline
Phase 3
494
Aichi, Aomori, Ehime, Fukuoka, Gifu, Gunma, Hyōgo, Kanagawa
2020-05-07
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Aichi, Hiroshima, Hyōgo, Niigata, Osaka, Saitama, Shizuoka, Tokyo
2019-11-13
Active, closed
Daiichi Sankyo
Phase 1/2
247
Aichi, Chiba, Hokkaido, Hyōgo, Kagawa, Osaka, Ōsaka-sayama, Saitama
2019-11-03
Recruiting
Stroke Thrombectomy and Aneurysm Registry
NCT04994756Stroke, Thromboses, Intracranial, Aneurysm, Brain
Medical University of South Carolina
Observational
40,000
Hyōgo
2019-09-17
Active, closed
Hoffmann-La Roche
Phase 3
257
Aichi, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kanagawa, Kumamoto
2018-08-16
Active, closed
Eisai Inc.
Phase 3
1,069
Aichi, Akita, Aomori, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo
2016-10-13
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Chūōku, Hyōgo, Kashiwa, Kurume, Nagoya, Niigata, Osaka, Tokyo
2016-05-24
Active, closed
Hoffmann-La Roche
Phase 2
534
Aichi, Chūō, Hyōgo, Matsuyama, Miyagi, Niigata, Osaka, Shizuoka
2015-11-19
Active, closed
Eli Lilly and Company
Phase 3
453
Amagasaki, Asahikawa, Bunkyō City, Fukuoka, Habikino, Hirakata, Hiroshima, Hyōgo
2014-10-03
Active, closed
Genentech, Inc.
Phase 2
378
Hiroshima, Hyōgo
2008-10-16
Rows per page Showing 1–86 of 86
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 October 2026. https://priyalifescience.com/clinical-trials-japan/city/hy-go

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 86 of those studies with a site in Hyōgo.

How many clinical trials are recruiting in Hyōgo?

28 of the 86 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 3 have not yet opened recruitment, 54 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hyōgo), 86 studies
PhaseStudiesRecruitingShare
Phase 3531961.6%
Phase 217519.8%
Observational525.8%
Not applicable414.7%
Phase 2/3313.5%
Phase 1/2202.3%
Phase 1101.2%
Phase 4101.2%

Most active sponsors

Lead sponsors with the most studies (Hyōgo)
Lead sponsorStudiesRecruiting
GlaxoSmithKline188
Hoffmann-La Roche164
Janssen Research & Development, LLC72
Gilead Sciences51
Ono Pharmaceutical Co., Ltd.43
Tokyo University42
Novo Nordisk A/S30
Amgen20
Daiichi Sankyo20
Genentech, Inc.20
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.